GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity

Prospective observational cohort study evaluating the early proctologic effects of GLP-1 receptor agonist therapy in morbidly obese patients. Participants will undergo baseline and 3-month anorectal symptom assessment and proctologic examination to evaluate newly developed proctologic diseases and changes in pre-existing symptoms.

Inclusion Criteria: * Age ≥18 years * Morbid obesity (BMI ≥40 kg/m² or BMI ≥35 kg/m² with obesity-related comorbidities) * Newly prescribed GLP-1 receptor agonist therapy * Ability and willingness to provide written informed consent * Ability to attend 3-month follow-up visit Exclusion Criteria: * Inflammatory bowel disease * Perianal Crohn's disease * History of anorectal malignancy * Previous pelvic radiotherapy * Anorectal surgery within the previous 3 months * Pregnancy * Neurogenic bowel dysfunction * Inability to comply with follow-up visits * Discontinuation of GLP-1 receptor agonist therapy before follow-up assessment * Active anorectal infection or abscess